Publications by authors named "Alexander Perl"

Claim this Profile
I
Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia.
Mark J Levis, Mehdi Hamadani, Brent R Logan, Richard J Jones, Anurag K Singh, Alexander E Perl

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FLT3-ITD measurable residual disease from the QuANTUM-First trial.
Mark J Levis, Harry P Erba, Pau Montesinos, Hee-Je Kim, Radovan Vrhovac, Alexander E Perl

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial.
Richard F Schlenk, Pau Montesinos, Hee-Je Kim, Antonio Romero-Aguilar, Radovan Vrhovac, Alexander E Perl

Haematologica· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
QuANTUM-First: Clinical Validation of the LeukoStrat Companion Diagnostic for the Selection of Patients With Acute Myeloid Leukemia Harboring FMS-Like Tyrosine Kinase 3-Internal Tandem Duplications for Treatment With Quizartinib.
Jaime E Connolly Rohrbach, Ken C N Chang, Maha Karnoub, Li Liu, Yasser Mostafa Kamel, Alexander E Perl

Arch Pathol Lab Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancing the Management of CH, MDS, and AML From the First Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.
Hetty E Carraway, Andrew M Brunner, Catherine E Lai, Marlise R Luskin, Jae Park, Alexander E Perl

Clin Lymphoma Myeloma Leuk· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.
Martha L Arellano, Michael J Thirman, John F DiPersio, Maël Heiblig, Eytan M Stein, Alexander E Perl

Blood· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Approaching a therapeutic inflection point for FLT3-mutated AML.
Alexander E Perl

Blood· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML.
Mark J Levis, Mehdi Hamadani, Brent R Logan, Richard J Jones, Anurag K Singh, Alexander E Perl

Blood· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen.
Margaret Rowe, Daria Babushok, Martin Carroll, Alison Carulli, Noelle Frey, Alexander Perl

Eur J Haematol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolving racial/ethnic disparities in AML survival in the novel therapy era.
Xin Wang, Phyllis A Gimotty, Andrew H Matthews, Ronac Mamtani, Selina M Luger, Alexander E Perl

Blood Adv· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Academic Community Partnership in Acute Promyelocytic Leukemia and Early Mortality: The ECOG-ACRIN EA9131 Trial.
Anand P Jillella, Sandra J Lee, Jessica K Altman, Selina M Luger, Martin S Tallman, Alexander E Perl

JAMA Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Menin Inhibition With Revumenib for -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).
Ghayas C Issa, Ibrahim Aldoss, Michael J Thirman, John DiPersio, Martha Arellano, Alexander Perl

J Clin Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acquired BCL2 variants associated with venetoclax resistance in acute myeloid leukemia.
Fiona C Brown, Xin Wang, Richard Birkinshaw, Chong Chyn Chua, Thomas Morley, Alexander E Perl

Blood Adv· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytokine-mediated CAR T therapy resistance in AML.
Anand S Bhagwat, Leonel Torres, Olga Shestova, Maksim Shestov, Patrick W Mellors, Alexander E Perl

Nat Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life with gilteritinib vs placebo posttransplant for FLT3-ITD+ acute myeloid leukemia.
Betty K Hamilton, Bhavik J Pandya, Cristina Ivanescu, Dina Elsouda, Mehdi Hamadani, Alexander E Perl

Blood Adv· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiomic single cell sequencing identifies stemlike nature of mixed phenotype acute leukemia.
Cheryl A C Peretz, Vanessa E Kennedy, Anushka Walia, Cyrille L Delley, Andrew Koh, Alexander E Perl

Nat Commun· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia.
Matthew P Connor, Neeharika Prathapa, Noelle V Frey, Saar I Gill, Elizabeth O Hexner, Alexander E Perl

Haematologica· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of .
Mark J Levis, Mehdi Hamadani, Brent Logan, Richard J Jones, Anurag K Singh, Alexander E Perl

J Clin Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia.
Mark Levis, Alexander Perl, Gary Schiller, Amir T Fathi, Gail Roboz

Blood Adv· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients.
Anthony D Sung, Thuy Koll, Shannon H Gier, Alessandro Racioppi, Griffin White, Alexander E Perl

Transplant Cell Ther· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers.
Yasmin Abaza, Eric S Winer, Guru Subramanian Guru Murthy, Rory M Shallis, Andrew H Matthews, Alexander E Perl

Am J Hematol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The FLT3 mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib.
Sunil K Joshi, Janét Pittsenbarger, Vanessa E Kennedy, Cheryl A C Peretz, Alexander E Perl

Am J Hematol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vitamin C deficiency in patients with acute myeloid leukemia: a case series and review of the literature.
Heather C Milbar, Avrom Caplan, Robert D Schwab, Alexandra J Coromilas, Emily Baumrin, Alexander Perl

Blood Adv· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Trial of Sirolimus with "7&3" Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia.
Neil Palmisiano, Grace Jeschke, Lindsay Wilde, Onder Alpdogan, Matthew Carabasi, Alexander Perl

Cancers (Basel)· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.
Keith W Pratz, Mohamad Cherry, Jessica K Altman, Brenda W Cooper, Nikolai A Podoltsev, Alexander E Perl

J Clin Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis